Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes

4 marzo 2016 aggiornato da: Takeda

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes

The purpose of this study is to determine the efficacy and safety of TAK-875 (fasiglifam), once daily (QD), in participants with type 2 diabetes mellitus (T2DM).

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

TAK-875 is being developed at Takeda Development Center, Inc. as an adjunct to diet and exercise to improve glycemic control in patients with T2DM.

This study will investigate TAK-875 in participants with type 2 diabetes mellitus who have been treated with only diet and exercise for at least 12 weeks prior to Screening, who have taken ≤7 days of any antidiabetic agent within the 12 weeks prior to Screening, and whose glycemic control is inadequate.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

421

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Argentina
      • Ciudad Autonoma Buenos Aires, Argentina
      • Cordoba, Argentina
      • Corrientes, Argentina
      • Mendoza, Argentina
    • Ciudad Autonoma Buenos Aires
      • Ciudad Autonoma de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina
    • Cordoba
      • Villa Cabrera, Cordoba, Argentina
  • Bulgaria
      • Byala, Bulgaria
      • Plovdiv, Bulgaria
      • Ruse, Bulgaria
      • Sofia, Bulgaria
      • Varna, Bulgaria
  • Guatemala
      • Guatemala, Guatemala
      • Guatemala City, Guatemala
      • Quetzaltenango, Guatemala
      • Zacapa, Guatemala
  • Messico
    • Distrito Federal
      • Mexico, Distrito Federal, Messico
    • Nuevo León
      • Monterrey, Nuevo León, Messico
  • Slovacchia
      • Banska Bystrica, Slovacchia
      • Bratislava, Slovacchia
      • Dolny Kubin, Slovacchia
      • Komarno, Slovacchia
      • Levice, Slovacchia
      • Pezinok, Slovacchia
      • Prievidza, Slovacchia
      • Trebisov, Slovacchia
      • Trencin, Slovacchia
      • Zilina, Slovacchia
  • Stati Uniti
    • Alabama
      • Dothan, Alabama, Stati Uniti
      • Muscle Shoals, Alabama, Stati Uniti
    • Arizona
      • Goodyear, Arizona, Stati Uniti
      • Phoenix, Arizona, Stati Uniti
    • California
      • Long Beach, California, Stati Uniti
      • North Hollywood, California, Stati Uniti
      • Norwalk, California, Stati Uniti
      • Palm Springs, California, Stati Uniti
      • Pismo Beach, California, Stati Uniti
    • Florida
      • Boynton Beach, Florida, Stati Uniti
      • Bradenton, Florida, Stati Uniti
      • Coral Gables, Florida, Stati Uniti
      • Hialeah, Florida, Stati Uniti
      • Largo, Florida, Stati Uniti
      • New Port Richey, Florida, Stati Uniti
      • Orlando, Florida, Stati Uniti
      • Pembroke Pines, Florida, Stati Uniti
    • Georgia
      • Decatur, Georgia, Stati Uniti
    • Illinois
      • Chicago, Illinois, Stati Uniti
    • Indiana
      • Avon, Indiana, Stati Uniti
      • Greenfield, Indiana, Stati Uniti
      • Muncie, Indiana, Stati Uniti
    • Iowa
      • Council Bluffs, Iowa, Stati Uniti
    • Kansas
      • Topeka, Kansas, Stati Uniti
    • Kentucky
      • Lexington, Kentucky, Stati Uniti
    • Maryland
      • Oxon Hill, Maryland, Stati Uniti
    • Michigan
      • Flint, Michigan, Stati Uniti
    • Mississippi
      • Picayune, Mississippi, Stati Uniti
    • Nebraska
      • Omaha, Nebraska, Stati Uniti
    • New Jersey
      • Elizabeth, New Jersey, Stati Uniti
    • North Carolina
      • Charlotte, North Carolina, Stati Uniti
      • Greensboro, North Carolina, Stati Uniti
      • Mooresville, North Carolina, Stati Uniti
      • Morganton, North Carolina, Stati Uniti
      • Raleigh, North Carolina, Stati Uniti
    • Ohio
      • Maumee, Ohio, Stati Uniti
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti
    • Pennsylvania
      • Harleysville, Pennsylvania, Stati Uniti
      • Levittown, Pennsylvania, Stati Uniti
      • Uniontown, Pennsylvania, Stati Uniti
    • South Carolina
      • Greer, South Carolina, Stati Uniti
    • Tennessee
      • Crossville, Tennessee, Stati Uniti
    • Texas
      • Carrollton, Texas, Stati Uniti
      • Dallas, Texas, Stati Uniti
      • El Pasco, Texas, Stati Uniti
      • Fort Worth, Texas, Stati Uniti
      • Ft. Worth, Texas, Stati Uniti
      • Houston, Texas, Stati Uniti
      • Irving, Texas, Stati Uniti
      • New Braunfels, Texas, Stati Uniti
      • San Antonio, Texas, Stati Uniti
      • Spring, Texas, Stati Uniti
      • Tomball, Texas, Stati Uniti
    • Utah
      • Salt Lake City, Utah, Stati Uniti
    • Virginia
      • Burke, Virginia, Stati Uniti
      • Manassas, Virginia, Stati Uniti
  • Ucraina
      • Dnipropetrovsk, Ucraina
      • Kharkiv, Ucraina
      • Kyiv, Ucraina
      • Odesa, Ucraina
      • Simferopol, Ucraina
      • Ternopil, Ucraina
      • Vinnytsia, Ucraina
      • Zaporizhzhia, Ucraina
  • Ungheria
      • Budapest, Ungheria
      • Debrecen, Ungheria
      • Kecskemet, Ungheria
      • Komarom, Ungheria
      • Szikszo, Ungheria
      • Zalaegerszeg, Ungheria

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  3. The participant is male or female and 18 years of age or older with a historical diagnosis of T2DM.
  4. The participant has been treated with only diet and exercise for at least 12 weeks prior to Screening and has an HbA1c concentration between 7.0 % and 10.5%, inclusive, at Screening.
  5. The participant has received ≤7 days of any antidiabetic agent within 12 weeks prior to Screening.
  6. The participant has a body mass index (BMI) ≤45 kg/m^2 at Screening.
  7. Participants regularly using other, non-excluded medications must be on a stable dose for at least 4 weeks prior to Screening. However, as needed (PRN) use of prescription or over-the-counter medication is allowed at the discretion of the investigator.
  8. The participant is able and willing to monitor glucose with a home glucose monitor and consistently record his or her own blood glucose concentrations and complete participant diaries.
  9. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of the informed consent throughout the duration of the study and for 30 days after the last dose of study drug.

Additional Inclusion Criteria prior to Randomization

  1. The participant has an HbA1c concentration between 7.0 and 10.5%, inclusive, and a fasting plasma glucose (FPG) ≤270 mg/dL (≤15.0 mmol/L) at Week -1 Visit. (If the participant does not qualify for randomization based on these criteria, the assessments may be repeated weekly, for a maximum of 2 additional weeks).
  2. The participant's overall compliance with single-blind study medication during the Placebo Run-in Period is at least 75% and does not exceed 125% based on tablet counts performed by the study staff.
  3. A female participant of childbearing potential must have a negative urine hCG pregnancy test at Baseline (Visit 4) prior to Randomization and prior to administration of the first dose of double-blind study medication

Exclusion Criteria:

  1. The participant has received any investigational compound within 30 days prior to Screening or has received an investigational antidiabetic drug within 3 months prior to Screening.
  2. The participant has been randomized in a previous TAK-875 study.
  3. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, or sibling; biological or legally adopted) or may consent under duress.
  4. The participant donated or received any blood products within 12 weeks prior to Screening or is planning to donate blood during the study.
  5. The participant has a hemoglobin ≤12 g/dL (≤120 gm/L) for males and ≤10 g/dL (≤100 gm/L) for females at Screening.
  6. The participant has a systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥95 mm Hg at Screening (If the participant meets this exclusion criterion, the assessment may be repeated once at least 30 minutes after the initial measurement and decision will be made based on the second measurement).
  7. The participant has a history of cancer that has been in remission for <5 years prior to Screening. A history of basal cell carcinoma or stage 1 squamous cell carcinoma of the skin is allowed.
  8. The participant has an alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels >2.0x the upper limit of normal (ULN) at Screening.
  9. The participant has a total bilirubin level greater than the ULN at Screening. Exception: if a participant has documented Gilbert's Syndrome, the participant will be allowed with an elevated bilirubin level per the investigator's discretion.
  10. The participant has a serum creatinine ≥1.5 mg/dL(≥133 µmol/L) [males] and ≥1.4 mg/dL (≥124 µmol/L) [females] and/or estimated glomerular filtration rate (GFR) <60 mL/min/1.73m^2 at Screening.
  11. The participant has uncontrolled thyroid disease.
  12. The participant has a history of laser treatment for proliferative diabetic retinopathy within 6 months prior to Screening.
  13. The participant has had gastric banding or gastric bypass surgery within one year prior to Screening.
  14. The participant has a known history of infection with human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV).
  15. The participant had coronary angioplasty, coronary stent placement, coronary bypass surgery, myocardial infarction, unstable angina pectoris, clinically significant abnormal electrocardiogram (ECG), cerebrovascular accident or transient ischemic attack within 3 months prior or at Screening.
  16. The participant has a history of hypersensitivity, allergies, or has had an anaphylactic reaction(s) to any component of TAK-875.
  17. The participant has a history of drug abuse (defined as illicit drug use) or a history of alcohol abuse within 2 years prior to Screening.
  18. The participant received excluded medications prior to Screening or is expected to receive excluded medication.
  19. If female, the participant is pregnant (confirmed by laboratory testing, i.e., serum human chorionic gonadotropin (hCG), in females of childbearing potential) or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  20. The participant is unable to understand verbal or written English or any other language for which a certified translation of the approved informed consent is available.
  21. The participant has any other physical or psychiatric disease or condition that in the judgment of the investigator may affect life expectancy or may make it difficult to successfully manage and follow the participant according to the protocol.

Additional Exclusion Criteria prior to Randomization

  1. The participant received excluded medications during the Placebo Run-in Period. (Topical and inhaled corticosteroids are allowed).
  2. The participant has a systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥95 mm Hg at Baseline (Visit 4) (If the participant meets this exclusion criterion, the assessment may be repeated once at least 30 minutes after the initial measurement and decision will be made based on the second measurement).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: Placebo
Fasiglifam placebo-matching tablets, orally, once daily for up to 24 weeks.
Droga: Placebo
Fasiglifam compresse corrispondenti al placebo
Sperimentale: Fasiglifam 25 mg
Fasiglifam 25 mg, tablets, orally, once daily for up to 24 weeks.
Droga: Fasiglifam
Fasiglifam compresse
Sperimentale: Fasiglifam 50 mg
Fasiglifam 50 mg, tablets, orally, once daily for up to 24 weeks.
Droga: Fasiglifam
Fasiglifam compresse

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
Lasso di tempo: Baseline and Week 24
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 24 relative to Baseline. A mixed model repeated measures (MMRM) model with treatment, country, visit and visit by treatment interaction as fixed factors and with Baseline value and Baseline value by visit interaction as covariates with an unstructured covariance structure was used for analysis.
Baseline and Week 24

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of HbA1c <7%
Lasso di tempo: Week 24
The incidence (percentage of participants with) HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of less than seven percent for target glycemic control at Week 24.
Week 24
Change From Baseline in Fasting Plasma Glucose
Lasso di tempo: Baseline and Week 24
The change between the fasting plasma glucose value collected at Week 24 relative to Baseline measured in milligrams per deciliter (mg/dL). A MMRM model with treatment, country, visit and visit by treatment interaction as fixed factors and with Baseline value and Baseline value by visit interaction as covariates with an unstructured covariance structure was used for analysis.
Baseline and Week 24
Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Meal Tolerance Test (MTT)
Lasso di tempo: Baseline and Week 24
The change between the value of glucose after a meal, measured by the meal tolerance test collected at Week 24 relative to Baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and 2 hours after the start of the meal measured in millimoles per liter (mmol/L). An Analysis of Covariance (ANCOVA) model with treatment and country as fixed factors and Baseline value as covariate was used for analysis.
Baseline and Week 24

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Takeda

Investigatori

  • Direttore dello studio: Senior Medical Director, Takeda

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 novembre 2011

Completamento primario (Effettivo)

1 luglio 2013

Completamento dello studio (Effettivo)

1 luglio 2013

Date di iscrizione allo studio

Primo inviato

18 ottobre 2011

Primo inviato che soddisfa i criteri di controllo qualità

18 ottobre 2011

Primo Inserito (Stima)

20 ottobre 2011

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

5 aprile 2016

Ultimo aggiornamento inviato che soddisfa i criteri QC

4 marzo 2016

Ultimo verificato

1 marzo 2016

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • TAK-875_301
  • 2011-002741-35 (Numero EudraCT)
  • U1111-1124-2154 (Identificatore di registro: WHO)

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi